GE Healthcare has announced the acquisition of SeqWright, a provider of nucleic acid sequencing and other genomic services.
GE Healthcare has announced the acquisition of SeqWright, a provider of nucleic acid sequencing and other genomic services.
This purchase complements Clarient, a unit of GE Healthcare, and provides a platform for Clarient to expand its clinical diagnostic offerings.
Pascale Witz, President and CEO of GE Healthcare, Medical Diagnostics, commented, “Combining the expertise and capabilities of the two companies will enable GE Healthcare to offer a substantially wider range of services to the biopharmaceutical, diagnostic and research industries and eventually to patients and health care providers.”
Fei Lu, President and CEO of SeqWright, said, “This partnership will put us in a position to apply the power of new direct detection technologies to clinical and companion diagnostics, potentially revolutionizing the way healthcare decisions are made.”
For more information please visit ref="http://www.gehealthcare.com">www.gehealthcare.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.